PMID- 10718182
OWN - NLM
STAT- MEDLINE
DCOM- 20000321
LR  - 20070702
IS  - 0748-7983 (Print)
IS  - 0748-7983 (Linking)
VI  - 26
IP  - 1
DP  - 2000 Feb
TI  - 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
PG  - 61-6
AB  - INTRODUCTION: The loss of heterozygosity (LOH) of 16q is a structural change 
      detected in about 20-30% of Wilms' tumour cases. Aberrations which result in 
      deletion of 16q are also found in breast cancer, prostate cancer and liver 
      cancer, where they are connected with a worse prognosis. The hypothesis of a bad 
      prognosis in nephroblastomas with LOH 16q was first formulated by scientists from 
      NWTS (National Wilms Tumor Study) on the basis of 232 cases of Wilms' tumour. 
      However, SIOP studies (International Society of Paediatric Oncology) which 
      included 28 cases of Wilms' tumour, did not show any clinico-pathological 
      correlations with LOH 16q. Therefore, we aimed to evaluate the importance of LOH 
      16q in relation to clinico-pathological factors in a group of children, treated 
      according to the SIOP criteria. AIMS: The aim of this work was to evaluate the 
      frequency of LOH 16q in sporadic unilateral Wilms' tumour and to study the 
      relationship between LOH 16q and selected patho-clinical parameters. The study 
      comprised 66 children (31 girls and 35 boys) aged from 2 days to 13 years. 
      METHODS: LOH 16q was studied by the examination of polymorphism of marker 
      sequences in the region 16q24. DNA was isolated from paraffin sections of tissue 
      for routine microscopic examination by the microdissection method. The method of 
      study involved the amplification of polymorphic sequences from the 16q24 region 
      by polymerase chain reaction (PCR) and separation of the products of 
      amplification by polyacrylamide gel electrophoresis. The results were the subject 
      of statistical analysis in relation to gender, age of child at first diagnosis, 
      stage of clinical advancement and histological type of tumour. The connection 
      between LOH 16q and recurrences, metastases and death, and failure free survival 
      and absolute survival of children followed-up for over 24 months after 
      nephrectomy were studied. RESULTS: The study revealed a lack of correlation 
      between LOH 16q and gender, however LOH 16q was more frequent in children with 
      Wilms' tumour aged >24 months, P<0.05. Also, LOH 16q was more frequent in tumours 
      classified as clinical stage (CS) II or III than in CS I, P<0.05, but there were 
      no differences in the occurrence of LOH 16q in tumours classified as CS II and CS 
      III. We have found no correlation between LOH 16q and the histological type of 
      tumour. However, LOH 16q has been found three times as frequently in tumours from 
      children who died than in tumours of children who survived, P<0.0024.
FAU - Skotnicka-Klonowicz, G
AU  - Skotnicka-Klonowicz G
AD  - Clinic of Surgery and Paediatric Oncology, Institute of Paediatrics, Medical 
      University of Lodz, Poland.
FAU - Rieske, P
AU  - Rieske P
FAU - Bartkowiak, J
AU  - Bartkowiak J
FAU - Szymik-Kantorowicz, S
AU  - Szymik-Kantorowicz S
FAU - Daszkiewicz, P
AU  - Daszkiewicz P
FAU - Debiec-Rychter, M
AU  - Debiec-Rychter M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Eur J Surg Oncol
JT  - European journal of surgical oncology : the journal of the European Society of 
      Surgical Oncology and the British Association of Surgical Oncology
JID - 8504356
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Child, Preschool
MH  - Chromosomes, Human, Pair 16/*genetics
MH  - Disease-Free Survival
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - Genes, Wilms Tumor/genetics
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kidney Neoplasms/*genetics/*pathology
MH  - *Loss of Heterozygosity
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Polymorphism, Genetic
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
MH  - Survival Analysis
MH  - Wilms Tumor/*genetics/*pathology
EDAT- 2000/03/16 09:00
MHDA- 2000/03/25 09:00
CRDT- 2000/03/16 09:00
PHST- 2000/03/16 09:00 [pubmed]
PHST- 2000/03/25 09:00 [medline]
PHST- 2000/03/16 09:00 [entrez]
AID - S0748-7983(99)90742-4 [pii]
AID - 10.1053/ejso.1999.0742 [doi]
PST - ppublish
SO  - Eur J Surg Oncol. 2000 Feb;26(1):61-6. doi: 10.1053/ejso.1999.0742.